| Company Name: | Warner Chilcott PLC | | Ticker Symbol: | WCRX | | | WWW Address: | www.warnerchilcott.com | | CEO: | Roger M. Boissonneault | | No. of Employees: | 1,115 | | Common Issue Type: | CS | | Business Description: | The Company is a specialty pharmaceutical company that develops, manufactures, markets and sells branded prescription pharmaceutical products currently focused on two therapeutic categories: women's healthcare and dermatology
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Other [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 23.8 |  0.55 | 23.75 | 24.23 | 23.49 | 23.46 | 22.98 | 2083619 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 5,985.7 | 251.5 | 0.91 | -0.03 | 0.00 | 14.4 | 0.0 | 24.45 - 9.24 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 23.25 | $ | | PE Ratio - LTM | 14.4 | |
| Market Capitalisation | 5,846.2 | mil |
| Latest Shares Outstanding | 251.5 | mil |
| Earnings pS (EPS) | -0.03 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 841,368 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 243.4 | mil |
| Float as % of Shares Outstanding | 96.8 | % |
| Foreign Sales | 29 | mil |
| Domestic Sales | 909 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 20.50 | % |
| Research & Devlopment (R&D) as % of Revenue | 6.30 | % |
| Gross Profit Margin | 83.9 | % |
| EBITDA Margin | 57.0 | % |
| Pre-Tax Profit Margin | 45.8 | % |
| Assets Turnover | 0.4 | % |
| Return on Assets (ROA) | 15.0 | % |
| Return on Equity (ROE) | 21.5 | % |
| Return on Capital Invested (ROCI) | 17.9 | % |
| Current Ratio | 2.9 | |
| Leverage Ratio (Assets/Equity) | 1.4 | |
| Interest Cover | 6.8 | |
| Total Debt/Equity (Gearing Ratio) | 0.20 | |
| LT Debt/Total Capital | 17.0 | % |
| Working Capital pS | 2.64 | $ |
| Cash pS | 3.00 | $ |
| Book-Value pS | 7.53 | $ |
| Tangible Book-Value pS | 1.13 | $ |
| Cash Flow pS | 2.67 | $ |
| Free Cash Flow pS | 1.56 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.09 | |
| Price/Tangible Book Ratio | 20.62 | |
| Price/Cash Flow | 8.7 | |
| Price/Free Cash Flow | 14.9 | |
| P/E as % of Industry Group | 64.0 | % |
| P/E as % of Sector Segment | 17.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 1.2 | 100 | 21,132 | 20,993 |
| 4 Weeks | 24.21 | 21.53 | 22.15 | 5.0 | 98 | 18,426 | 294,818 |
| 13 Weeks | 24.45 | 19.02 | 20.65 | 12.6 | 105 | 16,238 | 974,286 |
| 26 Weeks | 24.45 | 11.96 | 13.16 | 76.7 | 147 | 15,169 | 1,880,956 |
| 52 Weeks | 24.45 | 9.24 | 13.25 | 75.5 | 142 | 12,825 | 3,180,579 |
| YTD | 24.45 | 9.24 | - | 60.3 | 131 | 13,146 | 2,971,034 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 23.49 | 23.29 | 22.46 | 17.34 | 15.46 | 0.91 | 0.91 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 12.81 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | -72.86 |
| R&D | 0.00 | NA | 18.24 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 7.8 | 9.0 | 4.3 |
| Earnings % | 387.9 | 958.3 | -100.0 |
| EPS % | 386.0 | 956.3 | -100.0 |
| EPS $ | 1.66 | 1.53 | -0.15 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 3.25 |
| Current Ratio | 1.5 |
| Quick Ratio (Acid Test) | 0.7 |
| Liquidity Ratio (Cash) | 0.21 |
| Receivables Turnover | 12.1 |
| Average Collection Period | 30 |
| Working Capital/Equity | 6.2 |
| Working Capital pS | 0.33 |
| Cash-Flow pS | 0.94 |
| Free Cash-Flow pS | 0.96 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 3.43 |
| Financial Leverage Ratio (Assets/Equity) | 1.9 |
| Debt Ratio | 47.7 |
| Total Debt/Equity (Gearing Ratio) | 0.71 |
| LT Debt/Equity | 0.71 |
| LT Debt/Capital Invested | 46.0 |
| LT Debt/Total Liabilities | 77.8 |
| Interest Cover | 1.2 |
| Interest/Capital Invested | 3.92 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 9.21 |
| Tobin's Q Ratio | 2.27 |
| Current P/E Ratio - LTM | 14.40 |
| Enterprise Value (EV)/EBITDA | 13.60 |
| Enterprise Value (EV)/Free Cash Flow | 27.96 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 20.62 |
| Price/Book Ratio - LTM | 3.09 |
| Price/Cash Flow Ratio | 8.7 |
| Price/Free Cash Flow Ratio - LTM | 14.9 |
| Price/Sales Ratio | 5.89 |
| P/E Ratio (1 month ago) - LTM | 13.9 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 26.5 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 64.0 |
| P/E as % of Sector Segment | 17.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 10.2 |
| PER SHARE FIGURES |
| LT Debt pS | 3.81 |
| Current Liabilities pS | 0.67 |
| Tangible Book Value pS - LTM | 1.13 |
| Book Value pS - LTM | 7.53 |
| Capital Invested pS | 9.17 |
| Cash pS - LTM | 3.00 |
| Cash Flow pS - LTM | 2.67 |
| Free Cash Flow pS - LTM | 1.56 |
| Earnings pS (EPS) | -0.03 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 25.73 |
| Free Cash Flow Margin 5YEAR AVG | -135.31 |
| Net Profit Margin | -0.9 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.69 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.41 |
| Return on Capital Invested (ROCI) | -0.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 0.0 |
| Assets Productivity | 0.30 |
| Return on Assets (ROA) | -0.3 |
| Return on Assets (ROA) - 5YEAR AVRG. | 0.0 |
| Gross Profit Margin | 83.9 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 57.0 |
| EBIT Margin - LTM | 53.7 |
| Pre-Tax Profit Margin | 1.7 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 151.0 |
| Effective Tax Rate - 5YEAR AVRG. | 49.8 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 147 |
| Revenue per Employee | 841,368 |
| Net Income per Employee | -7,495 |
| Average Collection Period | 34 |
| Receivables Turnover | 12.1 |
| Day's Inventory Turnover Ratio | 113 |
| Inventory Turnover | 3.2 |
| Inventory/Sales | 6.2 |
| Accounts Payble/Sales | 1.49 |
| Assets/Revenue | 3.33 |
| Net Working Capital Turnover | 11.20 |
| Fixed Assets Turnover | 0.40 |
| Total Assets Turnover | 0.3 |
| Revenue per $ Cash | 26.13 |
| Revenue per $ Plant | 15.40 |
| Revenue per $ Common Equity | 0.69 |
| Revenue per $ Capital Invested | 0.41 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 20.5 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
| Research & Devlopment (R&D) as % of Revenue | 5.3 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 5.3 |
|
|  
|
| |
 |  |